Abstract
Neoadjuvant therapy is frequently used as a bridging treatment to transplantation, but its effectiveness on dropout rates has had conflicting reports. This study aims to demonstrate neoadjuvant therapy's role in improving dropout rates in patients with HCC within Milan criteria.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.